GE HealthCare (GEHC)
Health Care · medical devices and diagnostics · NASDAQ
GE HealthCare is a leading global medical technology provider delivering advanced diagnostic imaging, clinical systems, and intelligent digital solutions to healthcare providers worldwide.
What GE HealthCare does
GE HealthCare is a global medical technology company that develops, manufactures, and markets a broad range of medical systems, diagnostic imaging products, and digital healthcare solutions. The company provides essential equipment and services used in the diagnosis, treatment, and monitoring of patients, as well as pharmaceutical diagnostics. Its operations are focused on integrating hardware with software, artificial intelligence, and data analytics to improve clinical outcomes and operational efficiency for healthcare providers.
Themes: medical imaging, digital health, artificial intelligence in healthcare, precision medicine, medical diagnostics, clinical software platforms, patient monitoring, healthcare IT infrastructure
Fundamentals
- Price$64.22 as of 2026-10-08 close
- Market cap$29.2B as of 2026-04-22 (share count; price 2026-10-08)
- 1-year return-14.5% 2025-10-08 close $75.13 → 2026-10-08 close $64.22
- P/E14.77 as of 2026-10-08
- Net margin+10.1% FY2025, SEC XBRL
- Gross margin+40.0% FY2025, SEC XBRL
- ROE+20.1% FY2025, SEC XBRL
- Debt / equity0.92 as of 2026-09-03
- Revenue growth (YoY)+6.5% as of 2026-09-03
- Revenue CAGR (3y)+4.0% SEC XBRL
- Beta1.08 as of 2026-09-03
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.2%; at least 3 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How GEHC compares in its sector
- price-to-earnings ratiobottom 25% 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- gross marginbottom 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldbottom 10% 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
GEHC is not currently in any published Top 10 list. Its scores are below.
Top 10 score
47.1 #899 of 1,379 scored · #107 of 151 in Health Care
Valuation 72nd (price to earnings 14.8, price to book 2.7) and profitability 65th (return on equity 20.1%, operating margin 13.4%); weakest is trend (27th, a "death cross" — its 50-day average is below its 200-day).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, GEHC's dividend was covered by reported results (earnings payout 3%, free-cash-flow payout 4%). This describes past coverage, not a forecast.
- Earnings payout3% dividends / net income
- Free-cash-flow payout4% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How GE HealthCare looks technically
GE HealthCare (GEHC) is trading 9.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 124 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 17 trading days ago. It is 28.5% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 9.9% below its 200-day average, the long-term trend line — a long-term downtrend | -9.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $68.75 | $68.75 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $71.31 | $71.31 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 67.1. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 124 trading days ago — a "death cross", a bearish long-term signal | 124 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 18.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 39.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($63.31 to $67.10) — its "stochastic" reading is 24 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 23.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $89.77 | $89.77 |
|---|---|---|
| From the 52-week high | it is 28.5% below its 52-week high (its highest price of the past year) | -28.5% |
| Above the 52-week low | it is 9.3% above its 52-week low (its lowest price of the past year) | +9.3% |
| Below the 52-week high | it is 28.5% below its highest point of the past year | 28.5% |
| Since a 20-day breakout | it made a new 20-day low about 17 trading days ago | 17 sessions |
| Since a 55-day breakout | it made a new 55-day high about 34 trading days ago | 34 sessions |
| All-time high | its highest closing price on record is $94.80 (set on 2025-02-13) | $94.80 |
| Given back of the 52-week move | over the past year its closes ranged ($59.48 to $88.16), and it has recovered roughly a quarter of its fall from last year’s high — 17% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $77.21 to $78.12. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 16.5% |
| From the all-time high | it is 32.3% below its all-time high | -32.3% |
| Nearest price level | it is trading 3.5% below a resistance level at $66.48 — a price it turned at six times since 2025-05-07, most recently on 2026-09-28. Since 2024-10-08 it has 1 such level below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.5% |
| All-time low | its lowest closing price on record is $53.50 (set on 2023-01-04) | $53.50 |
| Above the all-time low | it is 20.0% above its all-time low | +20.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.54 between its high and its low — about 2.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.54 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $62.96 and $67.12 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $62.96 – $65.04 – $67.12 |
| Typical daily range (% of price) | its price moves about 2.4% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.4% |
| Stretch from the 200-day average | it is trading 4.6 daily ranges below its 200-day average price (9.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.37× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.4% |
|---|---|---|
| Open gap | it gapped 2.4% above the previous close 52 sessions ago and has not traded back through the level it left behind at 60.58 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.4% |
| Gap filled | a 2.3% gap up opened on 2026-09-22 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it took 7 sessions to close | 5 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -2.31% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 4.9 percentage points (the stock lost 3.8% while the market gained 1.0%) | -4.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 4.5 percentage points (the stock lost 0.7% while the market gained 3.8%) | -4.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 26.2 percentage points (the stock lost 8.8% while the market gained 17.5%) | -26.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 29.5 percentage points (the stock lost 14.5% while the market gained 15.0%) | -29.5% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.6% of the share price. | -5.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $68.97 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -6.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-07-23 (its 8-K), so the typical buyer over that stretch is under water. That average is $67.62 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | -5.0% |
Symmetrical triangle, either side — broke out · the lower entry $64.26 · 53 sessions in
Head and shoulders, bearish — broke down · entry $64.36 · 59 sessions in
Price levels it has turned at before
GEHC last closed at $64.22 on 2026-10-08. Since 2024-10-08 it has turned at 1 price below its last close and 11 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $66.48 | Resistance | 3.5% above the last close | turned there six times · 2025-05-07 to 2026-09-28 |
| $60.34 | Support | 6.0% below the last close | turned there six times · 2025-04-21 to 2026-07-24 |
| $69.26 | Resistance | 7.8% above the last close | turned there 10 times · 2025-05-22 to 2026-03-30 |
| $72.10 | Resistance | 12.3% above the last close | turned there five times · 2025-04-30 to 2026-07-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $67.10.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · lagging the market · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.76 mean, 1=Strong Buy…5=Strong Sell) — 20 analysts
- Mean price target$82.90 range $70.00 – $96.00; median $84.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GEHC
- Consensus EPS estimate$1.21 next reporting period, as of 2026-10-09
- Estimate change, 30 days+$0.0023 (+0.2%) from $1.20, on 2026-09-04, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Highly competitive markets and pressure on healthcare reimbursement rates.","Geopolitical instability, including trade and tariff policies and operations in China.","Operational risks related to complex global supply chains and information technology/cybersecurity security."]
What changed in the latest 10-Q
AI-assisted comparison of GEHC's 10-Q filed 2026-07-29 against the prior one filed 2026-04-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states MD&A covers the three and six months ended June 30, 2026 and 2025; older filing covered only the three months ended March 31, 2026 and 2025.
- Newer filing describes a strategic change in the second quarter of 2026 combining Imaging and Advanced Visualization Solutions ('AVS') into a new reportable segment, Advanced Imaging Solutions ('AIS'), resulting in three reportable segments: AIS, Pharmaceutical Diagnostics ('PDx'), and Patient Care Solutions ('PCS').
- Newer filing states historical segment financial information has been recast to conform to the new reportable segment structure.
- Newer filing states tariffs negatively impacted Operating income by $68 million and $156 million for the three and six months ended June 30, 2026, respectively, and $43 million and $52 million for the three and six months ended June 30, 2025, respectively.
- Newer filing states tariff impacts on cash flows were $63 million and $175 million for the three and six months ended June 30, 2026, respectively, and $87 million and $95 million for the three and six months ended June 30, 2025, respectively.
- Newer filing states tariff impacts are exclusive of any benefits from tariff refunds.
- Newer filing states the Company submitted refund claims in the second quarter of 2026, received $107 million of refunds, and recorded a $38 million receivable for submitted claims not yet reimbursed within Receivables - net of allowances.
- Newer filing states pre-tax benefits from tariff refunds of $106 million related to tariffs incurred in 2025 and $23 million related to tariffs incurred in 2026 were recognized in the second quarter of 2026, recorded within Cost of products sold and Cost of services sold.
- Newer filing states the Company intends to continue to file claims for additional tariff refunds, predominantly related to tariffs incurred in 2025.
- Newer filing adds a new subsection titled 'Other Geopolitical and Macroeconomic Uncertainties' discussing the conflict in the Middle East adversely impacting costs, supply chains, and logistics during the second quarter of 2026.
- Newer filing includes discussion of monitoring key raw materials including memory chips, logistics (inclusive of freight), and other costs linked to the price of oil.
- Removed:
- Older filing stated GE HealthCare's operations were organized and managed through four reportable segments: Imaging, Advanced Visualization Solutions ('AVS'), Patient Care Solutions ('PCS'), and Pharmaceutical Diagnostics ('PDx').
- Older filing included a paragraph stating that on January 3, 2023, General Electric Company, which now operates as GE Aerospace ('GE'), completed the spin-off of GE HealthCare Technologies Inc. (the 'Spin-Off').
- Older filing stated several countries announced tariffs on U.S. imports in response to U.S. tariffs.
- Older filing stated the U.S. subsequently imposed new tariffs under alternative statutory authority after the Supreme Court ruling.
- Older filing stated tariffs materially impacted Operating income by approximately $90 million and cash flows by approximately $110 million for the three months ended March 31, 2026, primarily from bilateral U.S. and Chinese tariffs and U.S. tariffs on all other global import suppliers.
- Older filing included a 'China Market' subsection discussing government policy focus on expanding healthcare access, increased competition from local companies, and volume based procurement policies.
- Older filing included a 'Russia and Ukraine Conflict' subsection with asset and revenue figures, sanctions discussion, and licensing requirements for Russia and Ukraine.
- Reworded:
- Older filing described the tariff refund process as announced for requesting refunds with timing and amount uncertain; newer filing describes the Company's actual submission of claims, receipt of refunds, and recognition of pre-tax benefits.
- Older filing described the tariff situation as 'fluid' with current-period impact estimates; newer filing presents specific three- and six-month impact figures for both 2026 and 2025.
- Older filing included 'other restrictions on specific industries, such as pharmaceuticals' as a potential risk; newer filing does not include this specific example.
- Older filing referenced 'changes in government spending and reimbursement'; newer filing references 'changes in government procurement and reimbursement'.
- Newer filing includes 'other factors' language in the macro monitoring paragraph not present in the older filing.
- Notes:
- The newer filing text appears truncated at the end, mid-sentence, and older filing text also appears cut off, which may not capture all changes.
- Both excerpts are portions of the full MD&A section; some apparent additions or removals may reflect text outside the provided excerpts.
- The older filing excerpt contains what appears to be garbled or incomplete text near the end ('reasonably likel'), limiting full assessment.
Risk Factors
- Added:
- Newer filing (2026-07-29) adds exhibit 10.1 'One GE HealthCare Annual Bonus Plan' to the exhibit list.
- Newer filing (2026-07-29) changes the XBRL exhibit 101 description to reference the quarter ended June 30, 2026, and expands the listed statements to include three and six months ended June 30, 2026 and 2025.
- Removed:
- Older filing (2026-04-29) included exhibits 10.1 through 10.8 (Credit Agreement dated February 26, 2026; Amendment No. 1 to Credit Agreement; Offer Letter with Jeannette Bankes; 2026 RSU, Stock Option, Performance Stock Unit, New Hire RSU Grant Agreements; 2026 Global Addendum), which are removed in the newer filing.
- Older filing (2026-04-29) included the footnote marker '†' and redaction language regarding certain exhibit portions redacted pursuant to Item 601(b)(2)(ii) and Item 601(b)(10)(iv), which is removed in the newer filing.
- Reworded:
- Newer filing (2026-07-29) updates certification exhibit 31.1/31.2 descriptions to omit 'as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002'.
- Newer filing (2026-07-29) updates certification exhibit 32.1 description to omit 'as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002'.
- Newer filing (2026-07-29) updates the XBRL exhibit 101 description from 'quarter ended March 31, 2026' to 'quarter ended June 30, 2026'.
- Newer filing (2026-07-29) updates the signature date from April 29, 2026 to July 29, 2026.
- Newer filing (2026-07-29) updates issuer purchase table period rows from January-March 2026 to April-June 2026.
- Newer filing (2026-07-29) updates total shares purchased from 1,401,569 (at $71.35) to 3,276,004 (at $61.05).
- Newer filing (2026-07-29) updates approximate dollar value remaining under repurchase program to $500 million (from $700 million).
- Notes:
- The Risk Factors section text itself is identical in both filings: 'There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.' Changes reported are in the surrounding sections (Items 2, 5, 6 and signature) included in the provided excerpts.
- The requested section is 'Risk Factors', but the provided text excerpts include subsequent Items 2-6 and signatures from each filing; those changes are reported above.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-048 buys ($6M) · 0 sells — 8 buying insiders
Cluster buying: 8 different insiders reported open-market purchases (SEC code P) of GEHC within a 30-day window between 2026-04-30 and 2026-05-22. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-05-22. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GEHC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 6 matched disclosures for GEHC from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding GEHC as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 67,603,363
- Reported value $4,327,291,273
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about GEHC's institutional holders → See what each manager we track holds →
Short interest (FINRA)
GEHC had 16,909,543 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
GEHC had 3.72% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.54 days to cover at the same settlement.
- Reported short interest (shares) 16,909,543
- Short interest (% of shares outstanding) 3.72%
- Prior settlement (shares) 18,955,374
- Reported change -10.79%
- Days to cover (reported) 5.54
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Siemens Healthineers (SMMNY)
- Philips (PHG)
- Canon Medical Systems
- Fujifilm Healthcare
- Hologic (HOLX)
- Medtronic (MDT)
- Stryker (SYK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GEHC vs…
GE HealthCare is found in…
GEHC shows up in…
Frequently asked questions
What does GE HealthCare (GEHC) do?
GE HealthCare is a global medical technology company that develops, manufactures, and markets a broad range of medical systems, diagnostic imaging products, and digital healthcare solutions. The company provides essential equipment and services used in the diagnosis, treatment, and monitoring of patients, as well as pharmaceutical diagnostics.
What sector is GE HealthCare (GEHC) in?
GE HealthCare (GEHC) is classified in the Health Care sector. Its industry is medical devices and diagnostics. It trades on NASDAQ.
Does GEHC pay a dividend?
Yes — GE HealthCare (GEHC) pays a dividend, with an indicated yield of about 0.25% and at least 3 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-03). Informational only — not financial advice.
Who are GE HealthCare's (GEHC) competitors?
Notable peers of GE HealthCare (GEHC) include Siemens Healthineers, Philips, Canon Medical Systems, Fujifilm Healthcare and Hologic. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in GEHC?
Yes — we hold 6 matched STOCK Act disclosures for GEHC from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is GE HealthCare (GEHC) overbought or oversold right now?
GE HealthCare (GEHC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GEHC come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.